Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)

Market Cap	41.24B
Revenue (ttm)	6.56B
Net Income (ttm)	612.15M
Shares Out	855.14M
EPS (ttm)	0.71
PE Ratio	70.40
Forward PE	29.88
Dividend	0.30 (0.60%)
Ex-Dividend Date	Jun 17, 2025

Volume	11,248,870
Average Volume	10,102,561
Open	49.60
Previous Close	49.19
Day's Range	49.02 - 50.45
52-Week Range	41.61 - 71.90
Beta	0.85
RSI	41.89
Earnings Date	Mar 26, 2026

About SHE:300347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 10,185
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300347

Financial Performance

In 2024, SHE:300347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.